HUE049941T2 - 4-amino-2-(1H-pirazolo[3,4-B]piridin-3-il)-6-oxo-6,7-dihidro-5H-pirrolo[2,3-D]pirimidin származékok és a megfelelõ (1H-indazol-3-il) származékok mint CGMP modulátorok cardiovaskuláris betegségek kezelésére - Google Patents
4-amino-2-(1H-pirazolo[3,4-B]piridin-3-il)-6-oxo-6,7-dihidro-5H-pirrolo[2,3-D]pirimidin származékok és a megfelelõ (1H-indazol-3-il) származékok mint CGMP modulátorok cardiovaskuláris betegségek kezeléséreInfo
- Publication number
- HUE049941T2 HUE049941T2 HUE16823455A HUE16823455A HUE049941T2 HU E049941 T2 HUE049941 T2 HU E049941T2 HU E16823455 A HUE16823455 A HU E16823455A HU E16823455 A HUE16823455 A HU E16823455A HU E049941 T2 HUE049941 T2 HU E049941T2
- Authority
- HU
- Hungary
- Prior art keywords
- derivatives
- indazol
- pyrazolo
- pyrrolo
- pyridin
- Prior art date
Links
- -1 1h-indazol-3-yl Chemical group 0.000 title 1
- ATSCLNXOTFEDBO-UHFFFAOYSA-N 4-amino-2-(2H-pyrazolo[3,4-b]pyridin-3-yl)-5,7-dihydropyrrolo[2,3-d]pyrimidin-6-one Chemical class NC=1C2=C(N=C(N=1)C1=NNC3=NC=CC=C31)NC(C2)=O ATSCLNXOTFEDBO-UHFFFAOYSA-N 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/098251 WO2017107052A1 (en) | 2015-12-22 | 2015-12-22 | Soluble guanylate cyclase stimulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE049941T2 true HUE049941T2 (hu) | 2020-11-30 |
Family
ID=57758775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16823455A HUE049941T2 (hu) | 2015-12-22 | 2016-12-20 | 4-amino-2-(1H-pirazolo[3,4-B]piridin-3-il)-6-oxo-6,7-dihidro-5H-pirrolo[2,3-D]pirimidin származékok és a megfelelõ (1H-indazol-3-il) származékok mint CGMP modulátorok cardiovaskuláris betegségek kezelésére |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US10030027B2 (pl) |
| EP (1) | EP3394067B1 (pl) |
| JP (1) | JP6454448B2 (pl) |
| KR (1) | KR102191312B1 (pl) |
| CN (1) | CN108738320B (pl) |
| AR (1) | AR107154A1 (pl) |
| AU (1) | AU2016377364B2 (pl) |
| BR (1) | BR112018012579B8 (pl) |
| CA (1) | CA3009193C (pl) |
| CL (1) | CL2018001671A1 (pl) |
| CO (1) | CO2018006300A2 (pl) |
| CR (1) | CR20180330A (pl) |
| CY (1) | CY1123173T1 (pl) |
| DK (1) | DK3394067T3 (pl) |
| DO (1) | DOP2018000153A (pl) |
| EA (1) | EA036445B1 (pl) |
| EC (1) | ECSP18054606A (pl) |
| ES (1) | ES2794654T3 (pl) |
| GE (1) | GEP20207205B (pl) |
| HR (1) | HRP20200857T1 (pl) |
| HU (1) | HUE049941T2 (pl) |
| IL (1) | IL260020B (pl) |
| LT (1) | LT3394067T (pl) |
| ME (1) | ME03748B (pl) |
| MX (2) | MX376256B (pl) |
| MY (1) | MY194021A (pl) |
| NI (1) | NI201800069A (pl) |
| PE (1) | PE20181802A1 (pl) |
| PH (1) | PH12018501342B1 (pl) |
| PL (1) | PL3394067T3 (pl) |
| PT (1) | PT3394067T (pl) |
| RS (1) | RS60344B1 (pl) |
| SG (1) | SG11201805272XA (pl) |
| SI (1) | SI3394067T1 (pl) |
| SV (1) | SV2018005715A (pl) |
| TN (1) | TN2018000219A1 (pl) |
| TW (1) | TWI724079B (pl) |
| UA (1) | UA122264C2 (pl) |
| WO (2) | WO2017107052A1 (pl) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
| EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| CA3009474A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
| US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SG11201811414TA (en) | 2016-06-20 | 2019-01-30 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| US10308644B2 (en) | 2016-12-22 | 2019-06-04 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP4223369A1 (en) | 2016-12-22 | 2023-08-09 | Incyte Corporation | Immunomodulator compounds and methods of use |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| KR102615821B1 (ko) * | 2017-04-11 | 2023-12-21 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 불소-치환된 인다졸 화합물 및 이의 용도 |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| CN112752756B (zh) | 2018-05-11 | 2024-06-25 | 因赛特公司 | 作为PD-L1免疫调节剂的四氢-咪唑并[4,5-c]吡啶衍生物 |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| WO2020148379A1 (en) | 2019-01-17 | 2020-07-23 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之鹽 |
| JP7559059B2 (ja) | 2019-09-30 | 2024-10-01 | インサイト・コーポレイション | 免疫調節剤としてのピリド［３，２－ｄ］ピリミジン化合物 |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| IL302590A (en) | 2020-11-06 | 2023-07-01 | Incyte Corp | Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| MX2024004273A (es) * | 2021-10-13 | 2024-04-25 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivado triciclico de pirimidina y aplicacion farmaceutica del mismo. |
| JP2026521484A (ja) * | 2023-06-09 | 2026-06-30 | ハイスーク ファーマシューティカル グループ カンパニー リミテッド | ピロロ［２，３－ｄ］ピリミジン－４－アミン誘導体及びその医薬学的な応用 |
| EP4731208A2 (en) * | 2023-06-26 | 2026-04-29 | Merck Sharp & Dohme LLC | Processes for preparing crystalline soluble guanylate cyclase stimulators |
| EP4731209A1 (en) * | 2023-06-26 | 2026-04-29 | Merck Sharp & Dohme LLC | Processes for preparing soluble guanylate cyclase stimulators |
| WO2025016393A1 (zh) * | 2023-07-17 | 2025-01-23 | 海思科医药集团股份有限公司 | 一种4-氨基-吡咯并[2,3-d]嘧啶-6-酮衍生物及其在医药上的应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845079A (en) | 1985-01-23 | 1989-07-04 | Luly Jay R | Peptidylaminodiols |
| US5066643A (en) | 1985-02-19 | 1991-11-19 | Sandoz Ltd. | Fluorine and chlorine statine or statone containing peptides and method of use |
| US4894437A (en) | 1985-11-15 | 1990-01-16 | The Upjohn Company | Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(arylthio)alkyl moieties |
| US4885292A (en) | 1986-02-03 | 1989-12-05 | E. R. Squibb & Sons, Inc. | N-heterocyclic alcohol renin inhibitors |
| US5089471A (en) | 1987-10-01 | 1992-02-18 | G. D. Searle & Co. | Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents |
| US4980283A (en) | 1987-10-01 | 1990-12-25 | Merck & Co., Inc. | Renin-inhibitory pepstatin phenyl derivatives |
| US5034512A (en) | 1987-10-22 | 1991-07-23 | Warner-Lambert Company | Branched backbone renin inhibitors |
| US5063207A (en) | 1987-10-26 | 1991-11-05 | Warner-Lambert Company | Renin inhibitors, method for using them, and compositions containing them |
| US5055466A (en) | 1987-11-23 | 1991-10-08 | E. R. Squibb & Sons, Inc. | N-morpholino derivatives and their use as anti-hypertensive agents |
| US5036054A (en) | 1988-02-11 | 1991-07-30 | Warner-Lambert Company | Renin inhibitors containing alpha-heteroatom amino acids |
| US5036053A (en) | 1988-05-27 | 1991-07-30 | Warner-Lambert Company | Diol-containing renin inhibitors |
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5106835A (en) | 1988-12-27 | 1992-04-21 | American Cyanamid Company | Renin inhibitors |
| US5063208A (en) | 1989-07-26 | 1991-11-05 | Abbott Laboratories | Peptidyl aminodiol renin inhibitors |
| US5098924A (en) | 1989-09-15 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Diol sulfonamide and sulfinyl renin inhibitors |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5064965A (en) | 1990-03-08 | 1991-11-12 | American Home Products Corporation | Renin inhibitors |
| US5075451A (en) | 1990-03-08 | 1991-12-24 | American Home Products Corporation | Pyrrolimidazolones useful as renin inhibitors |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| US5071837A (en) | 1990-11-28 | 1991-12-10 | Warner-Lambert Company | Novel renin inhibiting peptides |
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19744027A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Substituierte Pyrazolo[3,4-b]pyridine, ihre Herstellung und Verwendung in Arzneimitteln |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| CZ297264B6 (cs) | 1998-09-09 | 2006-10-11 | Metabasis Therapeutics, Inc. | Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy |
| CA2415742A1 (en) | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| US6852738B2 (en) | 2001-01-30 | 2005-02-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CA2495943C (en) | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| WO2004019869A2 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| CA2512879A1 (en) | 2003-01-17 | 2004-08-12 | Soumya P. Sahoo | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| US20100179173A1 (en) | 2007-06-28 | 2010-07-15 | Daniel Guay | Substituted fused pyrimidines as antagonists of gpr105 activity |
| EP2174343A1 (en) | 2007-06-28 | 2010-04-14 | Semiconductor Energy Laboratory Co, Ltd. | Manufacturing method of semiconductor device |
| EP2178537A4 (en) | 2007-07-19 | 2011-08-17 | Merck Sharp & Dohme | BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
| CN101939053A (zh) | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| CA2743864A1 (en) * | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CA2753434C (en) | 2009-02-26 | 2014-07-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| UA107112C2 (uk) * | 2010-05-27 | 2014-11-25 | Мерк Шарп Енд Доме Корп. | Активатори розчинної гуанілатциклази |
| EP2590979A1 (de) | 2010-07-09 | 2013-05-15 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US20140171434A1 (en) | 2011-01-11 | 2014-06-19 | Bayer Pharma Aktiengessellschaft | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| WO2012143510A1 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung |
| CN103906752B (zh) | 2011-07-06 | 2016-08-24 | 拜耳知识产权有限责任公司 | 杂芳基取代的吡唑并吡啶及其用作可溶性鸟苷酸环化酶刺激剂的用途 |
| BR112014005110A2 (pt) | 2011-09-02 | 2017-04-18 | Bayer Ip Gmbh | pirimidinas aneladas substituídas e utilização das mesmas |
| DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
| AP2016008970A0 (en) | 2013-07-10 | 2016-01-31 | Bayer Pharma AG | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof |
| WO2015088885A1 (en) * | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP3079700B1 (en) | 2013-12-11 | 2020-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
| US10844064B2 (en) | 2014-09-17 | 2020-11-24 | Cyclerion Therapeutics, Inc. | sGC stimulators |
| TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
| US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
| EP3310782B1 (en) | 2015-05-28 | 2021-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
| KR20180094965A (ko) | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장 괄약근 기능장애의 치료를 위한 sGC 자극제의 용도 |
| WO2017107052A1 (en) | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
| US11357777B2 (en) | 2016-02-01 | 2022-06-14 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of nonalcoholic steatohepatitis (NASH) |
-
2015
- 2015-12-22 WO PCT/CN2015/098251 patent/WO2017107052A1/en not_active Ceased
-
2016
- 2016-12-20 RS RS20200620A patent/RS60344B1/sr unknown
- 2016-12-20 HU HUE16823455A patent/HUE049941T2/hu unknown
- 2016-12-20 AR ARP160103930A patent/AR107154A1/es active IP Right Grant
- 2016-12-20 US US15/384,429 patent/US10030027B2/en active Active
- 2016-12-20 KR KR1020187020705A patent/KR102191312B1/ko active Active
- 2016-12-20 CN CN201680075365.8A patent/CN108738320B/zh active Active
- 2016-12-20 TN TNP/2018/000219A patent/TN2018000219A1/en unknown
- 2016-12-20 PL PL16823455T patent/PL3394067T3/pl unknown
- 2016-12-20 CA CA3009193A patent/CA3009193C/en active Active
- 2016-12-20 SG SG11201805272XA patent/SG11201805272XA/en unknown
- 2016-12-20 GE GEAP202014831A patent/GEP20207205B/en unknown
- 2016-12-20 CR CR20180330A patent/CR20180330A/es unknown
- 2016-12-20 MX MX2018007728A patent/MX376256B/es active IP Right Grant
- 2016-12-20 TW TW105142318A patent/TWI724079B/zh active
- 2016-12-20 EP EP16823455.7A patent/EP3394067B1/en active Active
- 2016-12-20 DK DK16823455.7T patent/DK3394067T3/da active
- 2016-12-20 PE PE2018001156A patent/PE20181802A1/es unknown
- 2016-12-20 EA EA201891303A patent/EA036445B1/ru not_active IP Right Cessation
- 2016-12-20 BR BR112018012579A patent/BR112018012579B8/pt active IP Right Grant
- 2016-12-20 ES ES16823455T patent/ES2794654T3/es active Active
- 2016-12-20 PH PH1/2018/501342A patent/PH12018501342B1/en unknown
- 2016-12-20 JP JP2018532431A patent/JP6454448B2/ja active Active
- 2016-12-20 ME MEP-2020-103A patent/ME03748B/me unknown
- 2016-12-20 LT LTEP16823455.7T patent/LT3394067T/lt unknown
- 2016-12-20 HR HRP20200857TT patent/HRP20200857T1/hr unknown
- 2016-12-20 AU AU2016377364A patent/AU2016377364B2/en active Active
- 2016-12-20 WO PCT/US2016/067654 patent/WO2017112617A1/en not_active Ceased
- 2016-12-20 SI SI201630769T patent/SI3394067T1/sl unknown
- 2016-12-20 PT PT168234557T patent/PT3394067T/pt unknown
- 2016-12-20 MY MYPI2018001031A patent/MY194021A/en unknown
- 2016-12-20 UA UAA201808060A patent/UA122264C2/uk unknown
-
2018
- 2018-06-13 NI NI201800069A patent/NI201800069A/es unknown
- 2018-06-13 IL IL260020A patent/IL260020B/en active IP Right Grant
- 2018-06-18 CO CONC2018/0006300A patent/CO2018006300A2/es unknown
- 2018-06-19 CL CL2018001671A patent/CL2018001671A1/es unknown
- 2018-06-19 SV SV2018005715A patent/SV2018005715A/es unknown
- 2018-06-21 MX MX2020011080A patent/MX2020011080A/es unknown
- 2018-06-22 DO DO2018000153A patent/DOP2018000153A/es unknown
- 2018-06-27 US US16/019,964 patent/US10428076B2/en active Active
- 2018-07-19 EC ECSENADI201854606A patent/ECSP18054606A/es unknown
-
2020
- 2020-06-16 CY CY20201100547T patent/CY1123173T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL260020B (en) | 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and respectively (1h- indazol-3-yl) derivatives as cGMP activators for the treatment of cardiovascular diseases | |
| IL270909A (en) | Imidazo[1,2-a]pyrazine modulators of the adenosine a2a receptor | |
| IL260923B (en) | History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors | |
| MY185392A (en) | Jak1 inhibitors for the treatment of myelodysplastic syndromes | |
| SI3555097T1 (sl) | Imidazo(4,5-d)pirolo(2,3-b)piridinske spojine kot zaviralci janus kinaz | |
| IL255305A0 (en) | Synthesis of h1-pyrrolo[3,2-b]pyridine derivatives that modulate kinases | |
| ZA201808257B (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| SI2914594T1 (sl) | Amino substituirani imidazo(1,2-A)piridinkarboksamidi in njihova uporaba | |
| ZA201904236B (en) | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors | |
| ZA201800485B (en) | Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy | |
| DK3177627T3 (da) | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet | |
| SI3442975T1 (sl) | 1,5-dihidro-4h-pirazolo(3,4-d)pirimidin-4-oni in 1,5-dihidro-4h-pirazolo(4,3-c)piridin-4-oni kot pde1 inhibitorji | |
| IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
| ZA201605666B (en) | Pyrazolo[1,5-a]pyrimidines as antiviral compounds | |
| IL234772A0 (en) | History of 6-(4-(1-amino-3-hydroxycyclobutyl)phenyl)-5-phenyl(furo, thiano or pyrrolo)[3,2-d]pyrimidin-4-one for cancer treatment | |
| GB201802644D0 (en) | Monocyclic,thieno, pyrido and pyrrolo pyrimidine compounds and methods of use and manufacture of the same | |
| SI3723808T1 (sl) | Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov | |
| SI3723807T1 (sl) | Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov | |
| IL253427B (en) | The result of pyrazolo[3,4-d]pyrimidine and its use in the treatment of Jericho rose |